Mizuho analyst Anthony Petrone lowered the firm’s price target on Edwards Lifesciences to $85 from $100 and keeps a Buy rating on the shares. Citi "lingering headwinds," the analyst reduced 2023 and 2024 estimates by 3% to 4%. However, he believes Edwards "is still poised to maintain its lead position in Structural Heart longer-term."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EW:
- Edwards Lifesciences downgraded to Hold from Buy at Stifel
- Edwards Lifesciences call volume above normal and directionally bullish
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- Wolfe Research cuts Edwards Lifesciences to Peer Perform on macro, TAVR maturity
- Edwards Lifesciences downgraded to Peer Perform from Outperform at Wolfe Research